Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 11/20 | 0.55 |
| ▸ | NEK2 | P51955 | 10/20 | 0.44 |
| ▸ | CSF1R | P07333 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.41 |
| ▸ | STK3 | Q13188 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | BRSK1 | Q8TDC3 | 3/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.41 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.41 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2502737 | 0.90 | PLK1 (0.69) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL2498645 | 0.81 | PLK1 (0.62) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL2498646 | 0.77 | PLK1 (0.48) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL2504907 | 0.77 | PLK1 (0.55) | PLK1 | |
| SCHEMBL2503440 | 0.73 | PLK1 (0.80) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL2516541 | 0.71 | PLK1 (1.00) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL2502739 | 0.71 | PLK1 (0.76) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL2525811 | 0.71 | PLK1 (0.82) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL2500681 | 0.70 | PLK1 (0.64) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL2518373 | 0.68 | PLK1 (0.77) | PLK1NEK2CSF1RKDRLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813613-B1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-8030327-B2 | 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle | MDS K.K. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1813613-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103136-A1 | Novel Fused Imidazole Derivative | HRH4, H1-4, H1-3 | PLK1 4301/4885NEK2 2188/4885CSF1R 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.